Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
THE UNIVERSITY OF CHICAGO has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
THE UNIVERSITY OF CHICAGO is a SAM.gov-registered entity based in CHICAGO, IL 60637-5418. UEI ZUE9HKT2CLC9; CAGE 5E688; primary NAICS 611310. Compliance posture not provided. Active SAM registration.
Headquarters
CHICAGO, IL 60637-5418
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
UEIZUE9HKT2CLC9
CAGE5E688
Teaming
Ready to team with THE UNIVERSITY OF CHICAGO?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
Who THE UNIVERSITY OF CHICAGO has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.
Subcontractor to this prime · 1 sub-award · latest Feb 7, 2025
USTRANSCOM
“SERVICES: NONPRODUCT.”
UNIVERSITY OF MONTANA
UEI DAY7Z8ZD48Q3 · not in the directory yet
$1.3M
Subcontractor to this prime · 3 sub-awards · latest Aug 19, 2025
National Institutes of Health
“THE KHADER LAB AT THE UNIVERSITY OF CHICAGO IS EQUIPPED TO PRODUCE THE M72 AND 5AG ANTIGENS REQUIRED FOR THE
PROJECT AND WILL PROVIDE THEM AS NEEDED.”
“A. PRODUCT DEVELOPMENT ACTIVITIES
SPECIFICALLY, THE SUBCONTRACTOR SHALL:
1. PROVIDE THE EQUIPMENT, FACILITIES, PERSONNEL AND OTHER RESOURCES M72 PRODUCTION.
A. SUB-ACTIVITY: THE SUBCONTRACTOR WILL PRODUCE M72 ON SUFFICIENT QUANTITIES TO SUPPORT ALL FORMULATION AND PRE-CLINICAL ACTIVITIES UNDER THIS AWARD.
2. PROVIDE THE EQUIPMENT, FACILITIES, PERSONNEL AND OTHER RESOURCES FOR THE IN VITRO AND EX VIVO EVALUATION OF THE OPTIMIZED UM-1098 FORMULATIONS.
A. SUB-ACTIVITY: THE SUBCONTRACTOR WILL CONDUCT A SERIES OF ESTABLISHED IN VITRO ASSAYS FOR THE COMPARATIVE EVALUATION OF OPTIMIZED UM-1098 POTENCY AND RECEPTOR SPECIFICITY THROUGH CYTOKINE PROFILING AND RECEPTOR SPECIFICITY ASSAYS.
B. SUB-ACTIVITY: THE SUBCONTRACTOR WILL COMPLETE MULTIOMICS STUDIES TO IDENTIFY BIOMARKERS PREDICTING ANTIGEN-SPECIFIC ADAPTIVE IMMUNE RESPONSE, USING A SERIES OF SOPHISTICATED EX VIVO ASSAYS TO DETERMINE THE MECHANISMS OF VACCINE-MEDIATED IMMUNITY.
3. PROVIDE THE EQUIPMENT, FACILITIES, PERSONNEL AND OTHER RESOURCES FOR THE IN VIVO EVALUATION OF THE OPTIMIZED UM-1098 FORMULATIONS.
A. SUB-ACTIVITY: THE SUBCONTRACTOR WILL CONDUCT A COMPREHENSIVE IN VIVO EVALUATION OF THE SAFETY AND IMMUNOGENICITY OF THE OPTIMIZED UM-1098 FORMULATIONS IN MICE.
B. SUB-ACTIVITY: THE SUBCONTRACTOR WILL IDENTIFY THE OPTIMAL UM-1098 VACCINE FORMULATION, DOSE, AND TIMING.
C. SUB-ACTIVITY: THE SUBCONTRACTOR WILL COMPLETE A COMPREHENSIVE EVALUATION OF THE LEAD UM-1098 FORMULATIONS IN MURINE VACCINATION AND MTB CHALLENGE STUDIES IN WT AND HUMANIZED MINCLE/MCL MICE.
D. SUB-ACTIVITY: THE SUBCONTRACTOR WILL ASSESS THE PRE-CLINICAL (IND-ENABLING) SAFETY AND EFFICACY OF UM-1098 IN A NHP VACCINATION AND MTB CHALLENGE STUDY.
E. SUB-ACTIVITY: THE SUBCONTRACTOR WILL CONDUCT STUDIES TO ASSESS THE MECHANISMS OF VACCINE-MEDIATED IMMUNITY AND IMMUNOPATHOLOGY FOLLOWING PATHOGEN CHALLENGE.
B. QUALITY ASSURANCE, QUALITY CONTROL, DATA MANAGEMENT
SPECIFICALLY, THE SUBCONTRACTOR SHALL:
1. COMPLETE QUARTERLY, SEMI-ANNUAL AND ANNUAL TECHN”
Subcontractor to this prime · 3 sub-awards · latest Apr 9, 2026
National Institutes of Health
“DR.COBEY WILL LEAD THE LONGITUDINAL, EPIDEMIOLOGICAL, AND EVOLUTIONARY MODELING AS PART OF THE "PATHOGENESIS AND IMMUNE RESPONSE RESEARCH” COMPONENT, PROJECTS 1 AND 3. IN PROJECT 1,HER GROUP WILL DEVELOP INDIVIDUAL, LONGITUDINAL MODELS TO UNDERSTAND THE DEVELOPMENT OF IMMUNITY AND PROTECTION TO INFLUENZA OVER TIME, WITH A PARTICULAR FOCUS ON UNDERSTANDING THE EVOLUTION OF ANTIBODY SPECIFICITY AND CONSEQUENCES FOR PROTECTION AND TRANSMISSION. HER GROUP WILL ALSO PROVIDE BROAD STATISTICAL SUPPORT FOR THE WORK CONDUCTED IN PROJECT 1. DR.COBEY WITH CO-LEAD ALL ACTIVITIES IN PROJECT 3, WHICH FOCUSES ON PREDICTING VIRAL EVOLUTIONARY AND EPIDEMIOLOGICAL DYNAMICS ON A GLOBAL SCALE. HER GROUP WILL ALSO SUPPORT MODELING EFFORTS IN OTHER COMPONENTS OF THE CENTER, FOR INSTANCE, RELATED TO PROJECT 2 OR PANDEMIC PREPAREDNESS.”
“3. STATEMENT OF WORK
1. SCOPE: THE UNIVERSITY OF PENNSYLVANIA CENTER OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE (PENN-CEIRR) BRINGS TOGETHER RENOWNED RESEARCHERS AND CUTTING-EDGE TECHNOLOGIES TO DISCOVER NEW INFORMATION AND TOOLS NEEDED TO DECREASE THE MORTALITY AND MORBIDITY ASSOCIATED WITH INFLUENZA VIRUSES AND OTHER PATHOGENS.
2. TECHNICAL REQUIREMENTS. INDEPENDENTLY, AND NOT AS AN AGENT OF THE GOVERNMENT, THE CONTRACTOR SHALL FURNISH ALL NECESSARY SERVICES, QUALIFIED PROFESSIONAL, TECHNICAL, AND ADMINISTRATIVE PERSONNEL, MATERIAL, EQUIPMENT AND FACILITIES, NOT OTHERWISE PROVIDED BY THE GOVERNMENT UNDER THE TERMS OF THIS CONTRACT, AS NEEDED TO PERFORM THE TASKS SET FORTH BELOW. SPECIFICALLY, THE CONTRACTOR SHALL:”
Subcontractor to this prime · 1 sub-award · latest Aug 25, 2026
National Aeronautics and Space Administration
“PROVIDE ELECTRICAL/ELECTRONIC ENGINEERING SUPPORT SERVICES FOR THE STUDY, DESIGN, DEVELOPMENT, FABRICATION, INTEGRATION, TESTING, VERIFICATION, AND OPERATIONS OF SPACE FLIGHT, AIRBORNE, AND GROUND SYSTEM HARDWARE, INCLUDING DEVELOPMENT AND VALIDATION OF NEW TECHNOLOGIES TO ENABLE FUTURE SPACE AND SCIENCE MISSIONS.”
Subcontractors it has used
VALJUVANT CORPORATION
UEI T4F5N9JN1VN9 · not in the directory yet
$1.7M
Subcontracted by this company · 3 sub-awards · latest Mar 12, 2026
National Institutes of Health
“IN THIS PROJECT, WE PROPOSE TO DEVELOP A NEW TYPE OF ADJUVANTED VACCINE THAT BOTH ACTIVATES AND LIMITS THE
INNATE IMMUNE RESPONSE. IN PRELIMINARY WORK, WE SHOWED THAT ADDING MOLECULES THAT ALTER THE SIGNALING OF
THE NF- AND IRF PATHWAY IN COMBINATION WITH A WELL-CHARACTERIZED TLR AGONIST RESULTED IN NEAR-ZERO
SYSTEMIC INFLAMMATION WHILE MAINTAINING MINIMAL LOCAL INFLAMMATION. AT THE SAME TIME, ADDITION OF THIS
COMPOUND, PME-564, INCREASED AND MODIFIED ANTIBODY RESPONSES FOR SEVERAL COMMERCIAL VACCINES – MOST
NOTABLY FLUZONE. IN THIS WORK, WE PROPOSE TO FURTHER DEVELOP THIS COMPOUND, PME-564, ALONGSIDE A VACCINE,
TO FIND A SINGLE ADJUVANT FORMULATION WHICH CAN BE USED IN AN IMPROVED FLU VACCINE. WE HAVE TWO GOALS:
(1) FIND OPTIMIZED VACCINE FORMULATIONS THAT EFFECTIVELY LOWER SYSTEMIC INFLAMMATION AND ASSOCIATED
SIDE EFFECTS WHILE BOOSTING ANTIBODY RESPONSES. PAIRING THESE FORMULATIONS WITH THE HIGHEST PERFORMING
VACCINE PLATFORM TO DEVELOP VACCINE CANDIDATES.
(2) TEST THESE VACCINE CANDIDATES FOR PERFORMANCE, TOXICITY AND SAFETY USING MICE TO IDENTIFY A CANDIDATE
FOR TRANSITION TO PHASE I TESTING.
THIS NEW APPROACH ADDRESSES A LIMITATION IN CURRENT ADJUVANT TECHNOLOGY. ADJUVANTS TRANSITIONING OUT OF
BASIC DISCOVERY HAVE LIMITED METHODS TO CONTROL EXCESS INFLAMMATION IN THE FORM OF INCREASED CYTOKINES –
REPRESENTED BY EXCESS TNF--6 PRODUCTION. A PRIMARY EXAMPLE ARE TLR7/8 AGONISTS, WHICH HAVE
BEEN EFFECTIVE IN VACCINES AGAINST MANY DISEASES BUT HAVE STRUGGLED WITH FORMULATION AND THE
UNPREDICTABILITY OF SYSTEMIC INFLAMMATION AND TOXICITY.2–8 FORMULATIONS DO HELP ADDRESS THIS PROBLEM TO
SOME EXTENT, BUT THEY DO NOT ADDRESS THE FUNDAMENTAL ACTIVITY OF THE COMPOUND WHICH GENERATES A
LARGE INFLAMMATORY RESPONSE AT THE CELLULAR LEVEL. OUR APPROACH DIRECTLY TARGETS THE PATHWAY THAT
CAUSES THIS EXCESSIVE AND OFTEN SYSTEMIC INFLAMMATION AND REDUCES IT. THE ADDED BENEFIT IS THAT BECAUSE
THE MODULATION OCCURS INDEPENDENT OF THE AGONIST, IT CAN PROVIDE AN AD”
Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.
No GSA CALC+ rates on record
Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.
“TECHNICAL REQUIREMENTS
INDEPENDENTLY, AND NOT AS AN AGENT OF THE GOVERNMENT, THE SUBCONTRACTOR SHALL FURNISH ALL NECESSARY SERVICES, QUALIFIED PROFESSIONAL, TECHNICAL, AND ADMINISTRATIVE PERSONNEL, MATERIAL, EQUIPMENT AND FACILITIES, NOT OTHERWISE PROVIDED BY THE GOVERNMENT UNDER THE TERMS OF THIS SUBCONTRACT, AS NEEDED TO PERFORM THE TASKS SET FORTH BELOW.
A. PRODUCT DEVELOPMENT ACTIVITIES
SPECIFICALLY, THE SUBCONTRACTOR SHALL:
1. PROVIDE THE EQUIPMENT, FACILITIES, PERSONNEL AND OTHER RESOURCES M72 PRODUCTION.
A. SUB-ACTIVITY: THE SUBCONTRACTOR WILL PRODUCE M72 ON SUFFICIENT QUANTITIES TO SUPPORT ALL FORMULATION AND PRE-CLINICAL ACTIVITIES UNDER THIS AWARD.
2. PROVIDE THE EQUIPMENT, FACILITIES, PERSONNEL AND OTHER RESOURCES FOR THE IN VITRO AND EX VIVO EVALUATION OF THE OPTIMIZED UM-1098 FORMULATIONS.
A. SUB-ACTIVITY: THE SUBCONTRACTOR WILL CONDUCT A SERIES OF ESTABLISHED IN VITRO ASSAYS FOR THE COMPARATIVE EVALUATION OF OPTIMIZED UM-1098 POTENCY AND RECEPTOR SPECIFICITY THROUGH CYTOKINE PROFILING AND RECEPTOR SPECIFICITY ASSAYS.
B. SUB-ACTIVITY: THE SUBCONTRACTOR WILL COMPLETE MULTIOMICS STUDIES TO IDENTIFY BIOMARKERS PREDICTING ANTIGEN-SPECIFIC ADAPTIVE IMMUNE RESPONSE, USING A SERIES OF SOPHISTICATED EX VIVO ASSAYS TO DETERMINE THE MECHANISMS OF VACCINE-MEDIATED IMMUNITY.
3. PROVIDE THE EQUIPMENT, FACILITIES, PERSONNEL AND OTHER RESOURCES FOR THE IN VIVO EVALUATION OF THE OPTIMIZED UM-1098 FORMULATIONS.
A. SUB-ACTIVITY: THE SUBCONTRACTOR WILL CONDUCT A COMPREHENSIVE IN VIVO EVALUATION OF THE SAFETY AND IMMUNOGENICITY OF THE OPTIMIZED UM-1098 FORMULATIONS IN MICE.
B. SUB-ACTIVITY: THE SUBCONTRACTOR WILL IDENTIFY THE OPTIMAL UM-1098 VACCINE FORMULATION, DOSE, AND TIMING.
C. SUB-ACTIVITY: THE SUBCONTRACTOR WILL COMPLETE A COMPREHENSIVE EVALUATION OF THE LEAD UM-1098 FORMULATIONS IN MURINE VACCINATION AND MTB CHALLENGE STUDIES IN WT AND HUMANIZED MINCLE/MCL MICE.
D. SUB-ACTIVITY: THE SUBCONTRACTOR WILL ASSESS THE PRE-CLINICAL (IND-ENABLING) SAFETY AN”
“STATEMENT OF WORK
MY GROUP WILL BE ENGAGED IN TWO MAJOR ACTIVITIES AS PART OF THIS CEIRR CENTER:
1. LONGITUDINAL, EPIDEMIOLOGICAL, AND EVOLUTIONARY MODELING AS PART OF THE “PATHOGENESIS AND
IMMUNE RESPONSE RESEARCH” COMPONENT, PROJECTS 1 AND 3. IN PROJECT 1, WE WILL DEVELOP
INDIVIDUAL, LONGITUDINAL MODELS TO UNDERSTAND THE DEVELOPMENT OF IMMUNITY AND PROTECTION
TO INFLUENZA OVER TIME, WITH A PARTICULAR FOCUS ON UNDERSTANDING THE EVOLUTION OF ANTIBODY
SPECIFICITY AND CONSEQUENCES FOR PROTECTION AND TRANSMISSION. WE WILL ALSO PROVIDE BROAD
STATISTICAL SUPPORT FOR THE WORK CONDUCTED IN PROJECT 1. DR. COBEY WITH CO-LEAD ALL ACTIVITIES
IN PROJECT 3, WHICH FOCUSES ON PREDICTING VIRAL EVOLUTIONARY AND EPIDEMIOLOGICAL DYNAMICS
ON A GLOBAL SCALE. HER FOCUS WILL BE ON INTEGRATING AIMS 2 AND 3, WHICH INVOLVES FORECASTING
THE DYNAMICS OF CLADES, SUBTYPES, AND TYPES USING POPULATION-LEVEL TIMES SERIES OF CASES
AND IMMUNE PROFILES. THESE MODELS WILL FURTHER BE RECONCILED WITH THOSE IN PROJECT 1.
2. MY GROUP WILL LEAD THE COMPUTATIONAL CORE. THE CORE’S MAJOR ACTIVITIES WILL BE EXPANDED
ANALYSES USING DATA FROM MULTIPLE CENTERS TO (1) FORECAST VIRAL EVOLUTION AND EPIDEMIOLOGY,
(2) UNDERSTAND IMMUNE CORRELATES OF RISK, PROTECTION, VACCINE FAILURE, AND TRAMISSION, AND
(3) ANALYZE OTHER ASPECTS OF THE IMMUNE RESPONSE TO INFLUENZA, INFLUENZA DYNAMICS, AND
VACCINATION. ADDITIONALLY, WE WILL DEVELOP NOVEL BIOINFORMATIC TOOLS TO (4) INFER ANTIBODY
SPECIFICITY, (5) ASSESS SELECTION USING MUTANT LIBRARIES, (6) VISUALIZE VIRAL EVOLUTION, AND (7)
DEVELOP NEW ANTIGENIC MAPS GIVEN HOSTS’ COMPLEX IMMUNE HISTORIES. MY GROUP WILL
COORDINATE THESE ACTIVITIES AND TAKE THE LEAD ON SEVERAL, ESPECIALLY (2), (3), (4), AND (7). IN
ADDITION, WE WILL IDENTIFY MODELING OPPORTUNITIES AND COORDINATE MODELING EFFORTS BETWEEN
THE CENTERS, INCREASE MODELING CAPACITY, AND ASSIST WITH STUDY DESIGN AND DATA
INTEGRATION.
WE WILL ALSO SUPPORT MODELING EFFORTS IN OTHER COMPONENTS OF THE CENTER, FOR INSTANCE, RELATED”
“IN THIS PROJECT, WE PROPOSE TO DEVELOP A NEW TYPE OF ADJUVANTED VACCINE THAT BOTH ACTIVATES AND LIMITS THE
INNATE IMMUNE RESPONSE. IN PRELIMINARY WORK, WE SHOWED THAT ADDING MOLECULES THAT ALTER THE SIGNALING OF
THE NF- AND IRF PATHWAY IN COMBINATION WITH A WELL-CHARACTERIZED TLR AGONIST RESULTED IN NEAR-ZERO
SYSTEMIC INFLAMMATION WHILE MAINTAINING MINIMAL LOCAL INFLAMMATION. AT THE SAME TIME, ADDITION OF THIS
COMPOUND, PME-564, INCREASED AND MODIFIED ANTIBODY RESPONSES FOR SEVERAL COMMERCIAL VACCINES – MOST
NOTABLY FLUZONE. IN THIS WORK, WE PROPOSE TO FURTHER DEVELOP THIS COMPOUND, PME-564, ALONGSIDE MRNA
VACCINES TO FIND A SINGLE ADJUVANT FORMULATION THAT CAN BE USED IN AN IMPROVED H5N1 VACCINE.
WE HAVE TWO GOALS:
(1) IDENTIFY A FORMULATION CANDIDATE THAT CAN BE RAPIDLY ADMIXED WITH EITHER CURRENT QUADRIVALENT FLU
VACCINES OR MRNA VACCINES. PAIRING THESE FORMULATIONS WITH THE HIGHEST PERFORMING VACCINE PLATFORM
TO DEVELOP VACCINE CANDIDATES. IMPROVING REACTOGENICITY, REDUCING DOSAGE, AND INCREASING DURABILITY OF
EACH VACCINE.
(2) RAPIDLY TESTING THESE CANDIDATES FOR COMPATIBILITY WITH COMMERCIAL VACCINE SYSTEMS AND PRE-CLINICAL
PANDEMIC FLU VACCINES, DETERMINING AN APPROPRIATE TOXICITY AND SAFETY PROFILE FOR BOTH THE INDEPENDENT
AND MIXED FORMULATION.
THIS NEW APPROACH ADDRESSES A LIMITATION IN CURRENT ADJUVANT TECHNOLOGY. ADJUVANTS TRANSITIONING OUT OF
BASIC DISCOVERY HAVE LIMITED METHODS TO CONTROL EXCESS INFLAMMATION IN THE FORM OF INCREASED CYTOKINES –
REPRESENTED BY EXCESS TNF--6 PRODUCTION. THE FOCUS OF THIS SUPPLEMENTAL PROGRAM WILL BE THE COFORMULATION
OF THESE MOLECULES WITH MRNA VACCINES, SPECIFICALLY IN THE CONTEXT OF PANDEMIC FLU.
FORMULATIONS DO HELP ADDRESS THIS PROBLEM TO SOME EXTENT, BUT THEY DO NOT ADDRESS THE FUNDAMENTAL
ACTIVITY OF THE COMPOUND, WHICH GENERATES A LARGE INFLAMMATORY RESPONSE AT THE CELLULAR LEVEL. OUR
APPROACH DIRECTLY TARGETS THE PATHWAY THAT CAUSES THIS EXCESSIVE AND OFTEN SYSTEMIC INFLAMMATION AND
REDUCES I”
“3.1 SCOPE
IN THIS PROJECT, WE PROPOSE TO DEVELOP NEW IMMUNE-ENHANCING FORMULATIONS BY DISCOVERING AND
OPTIMIZING SMALL MOLECULE MODULATORS THAT IMPROVE INNATE IMMUNE ACTIVATION TO SUPPORT ENHANCED
T-CELL RESPONSES DURING VACCINATION. BUILDING ON PRELIMINARY WORK THAT IDENTIFIED PME-564 AS A
POTENT MODULATOR OF NF
RELATED COMPOUNDS THAT ACHIEVE AN OPTIMAL BALANCE OF IMMUNE ACTIVATION AND SAFETY. THESE
COMPOUNDS WILL BE TESTED IN MULTIPLE FORMULATION TYPES TO ASSESS THEIR ABILITY TO POTENTIATE VACCINEINDUCED
T-CELL RESPONSES WITHOUT INDUCING EXCESSIVE INFLAMMATION.
WE HAVE TWO GOALS:
(1) IDENTIFY A FORMULATION CANDIDATE THAT CAN BE RAPIDLY ADMIXED WITH EITHER CURRENT
QUADRIVALENT VACCINES OR VACCINES. PAIRING THESE FORMULATIONS WITH THE HIGHEST PERFORMING
VACCINE PLATFORM TO DEVELOP VACCINE CANDIDATES. IMPROVING REACTOGENICITY, REDUCING DOSAGE,
AND INCREASING DURABILITY OF EACH VACCINE.
PRE-CLINICAL NEXT-GENERATION VACCINES VACCINES, DETERMINING AN APPROPRIATE TOXICITY AND SAFETY
PROFILE FOR BOTH THE INDEPENDENT AND MIXED FORMULATION.
THIS NEW APPROACH ADDRESSES A LIMITATION IN CURRENT ADJUVANT TECHNOLOGY. ADJUVANTS TRANSITIONING
OUT OF BASIC DISCOVERY HAVE LIMITED METHODS TO CONTROL EXCESS INFLAMMATION IN THE FORM OF
INCREASED CYTOKINES – REPRESENTED BY EXCESS TNF 6 PRODUCTION. THE FOCUS OF THIS
SUPPLEMENTAL PROGRAM WILL BE THE CO-FORMULATION OF THESE MOLECULES WITH VACCINES, SPECIFICALLY
IN THE CONTEXT OF NEXT-GENERATION VACCINES. FORMULATIONS DO HELP ADDRESS THIS PROBLEM TO SOME
EXTENT, BUT THEY DO NOT ADDRESS THE FUNDAMENTAL ACTIVITY OF THE COMPOUND, WHICH GENERATES A LARGE
INFLAMMATORY RESPONSE AT THE CELLULAR LEVEL. OUR APPROACH DIRECTLY TARGETS THE PATHWAY THAT CAUSES
THIS EXCESSIVE AND OFTEN SYSTEMIC INFLAMMATION AND REDUCES IT. THE ADDED BENEFIT IS THAT BECAUSE
THE MODULATION OCCURS INDEPENDENTLY OF THE AGONIST, IT CAN PROVIDE AN ADDED BENEFIT NOT JUST TO A
SPECIFIC AGONIST BUT TO ANY , QUADRIVALENT, OR FLU VACCINE. THE RESULT IS COUNTER-INTUITIVE BUT
EMPIRIC”
Subcontracted by this company · 1 sub-award · latest Jan 27, 2026
National Institutes of Health
“INIMMUNE WILL ASSIST THE UNIVERSITY OF CHICAGO AS A SUBCONTRACTOR WITH THE OVERALL GOAL OF
DEVELOPING A NEW TYPE OF ADJUVANTED VACCINE THAT BOTH ACTIVATES AND LIMITS THE INNATE IMMUNE
RESPONSE. THIS NEW APPROACH ADDRESSES A LIMITATION IN CURRENT ADJUVANT TECHNOLOGY. ADJUVANTS
TRANSITIONING OUT OF BASIC DISCOVERY HAVE LIMITED METHODS TO CONTROL EXCESS INFLAMMATION IN THE
FORM OF INCREASED CYTOKINES – REPRESENTED BY EXCESS TNF- -6 PRODUCTION. A PRIMARY
VACCINES AGAINST MANY DISEASES BUT
HAVE STRUGGLED WITH FORMULATION AND THE UNPREDICTABILITY OF SYSTEMIC INFLAMMATION AND TOXICITY.
THE SPECIFIC ACTIVITIES INIMMUNE WILL PERFORM AS A SUBCONTRACTOR ARE OUTLINED BELOW:
YEAR 1 ACTIVITY: THE SUBCONTRACTOR SHALL ASSIST WITH THE DEVELOPMENT OF A SERIES OF MOLECULES
BASED ON A COMBINATION OF AN IMMUNE-MODULATOR (PME--
4001)
SUB-ACTIVITY: THE SUBCONTRACTOR SHALL PROVIDE CONSULTING SUPPORT FOR THE SYNTHESIS OF PME-
564 DERIVATIVES.
SUB-ACTIVITY: THE SUBCONTRACTOR SHALL SYNTHESIZE A SMALL-SCALE LOT OF INI-4001.
SUB-ACTIVITY: THE CONTRACTOR WILL PROVIDE CONSULTING IN THE DESIGN OF MOLECULES BASED ON
INITIAL RESULTS FOR SYNTHESIS OF SECOND SET OF TEST COMPOUNDS.
YEAR 2 ACTIVITY: THE SUBCONTRACTOR WILL PROVIDE FORMULATIONS FOR TESTING DERIVATIVES OF PME-564
(BAFETINIB) IN COMBINATION WITH INI-4001 FOR ACTIVITY AND SELECT TOP PERFORMERS FOR DEVELOPMENT AS
VACCINE CANDIDATES.
SUB-ACTIVITY: THE SUBCONTRACTOR WILL INITIATE LIPOSOME FORMULATION GENERATION AND TESTING.
SUB-ACTIVITY: THE SUBCONTRACTOR WILL INITIATE OIL-IN-WATER EMULSION FORMULATION AND DERIVATIVE
GENERATION AND TESTING.
YEAR 3 ACTIVITY: THE SUBCONTRACTOR SHALL CONTINUE WITH OPTIMIZATION AND DOWN-SELECTION OF
FORMULATIONS.
SUB-ACTIVITY: THE SUBCONTRACTOR WILL TEST LEAD FORMULATIONS FOR COMPATIBILITY WITH WHOLE VIRAL
PARTICLES, MRNA VACCINES AND HA PROTEINS.
SUB-ACTIVITY: THE SUBCONTRACTOR WILL COMPLETE THE ANALYT”
BAYLOR COLLEGE OF MEDICINE
UEI CQGQR443DCS3 · not in the directory yet
$468.8K
Subcontracted by this company · 1 sub-award · latest Mar 19, 2026
Defense Health Agency
“BAYLOR COLLEGE OF MEDICINE (BCM) WILL PARTICIPATE AS A SUBCONTRACTOR IN THE STUDY ENTITLED “PREDICTION AND
PREVENTION OF INTRACRANIAL HYPERTENSION AND TISSUE HYPOXIA IN SEVERE TRAUMATIC BRAIN INJURY” IN RESPONSE TO THE
FOA DEPARTMENT OF DEFENSE (DOD) TRAUMATIC BRAIN INJURY AND PSYCHOLOGICAL HEALTH RESEARCH PROGRAM
(TBIPHRP) CLINICAL TRIAL AWARD - RESEARCH LEVEL 1. UNIVERSITY OF CHICAGO WILL BE THE PRIME. BCM PERSONNEL
WILL IDENTIFY, CONSENT, AND PREFORM RESEARCH ON SUBJECTS WHO MEET STRUCT INCLUSION CRITERIA AS INDICATED BY AN
APPROVED IRB RESEARCH PROTOCOL, WHICH BCM PERSONNEL WILL ALSO HELP DRAFT AND SUBMIT FOR APPROVAL. BCM
PERSONNEL WILL RECORD ALL STUDY RELATED DATA, INCLUDING THE RECORDINGS OF PHYSIOLOGIC DATA FROM STUDY SUBJECTS
NEEDED FOR THE MACHINE LEARNING ANALYSIS. BCM PERSONNEL WILL COORDINATE AND ASSIST WITH THE DATA ANALYSIS
REQUIRED TO SUCCESSFULLY COMPLETE THE AIMS OUTLINED IN THE PROPOSAL. BCM PERSONNEL WILL ASSIST IN THE
DISCRIMINATION OF THE RESULTS OF THIS STUDY THROUGH THE CREATION AND SUBMISSION OF RESEARCH MANUSCRIPTS AND
SCIENTIFIC ABSTRACTS/PRESENTATIONS.”
EMORY UNIVERSITY
UEI U3YZCPD582F9 · not in the directory yet
$280.3K
Subcontracted by this company · 1 sub-award · latest Jun 9, 2026
National Institutes of Health
“FOR THIS CONTRACT, DR. TOMALKA WILL SERVE AS THE SITE PI FOR STUDIES CONDUCTED AT EMORY UNIVERSITY. HE WILL BE RESPONSIBLE FOR OVERSEEING THE COMPLETION OF THE SCREENING OF 500 ADJUVANT CANDIDATE FORMULATIONS IN PBMCS FOR THEIR CAPACITY TO MODULATE HUMAN T CELL FATE (I.E., TH1, TH2, TH17, TFH) BY FLOW CYTOMETRY AND CYTOKINE PRODUCTION OF KEY CYTOKINES ASSOCIATED WITH T CELL DIFFERENTIATION AND TH SUBSETS. THE 100 TOP COMPOUNDS FROM THIS SCREENING WILL BE TESTED IN PBMCS FROM RECENTLY INFLUENZA VACCINATED INDIVIDUALS IN THE PRESENCE OF INFLUENZA ANTIGEN TO VALIDATE THE MODULATION OF ANTIGEN-SPECIFIC T CELL FATES IN HUMAN CELLS BY FLOW CYTOMETRY AND CYTOKINE DETECTION AS BEFORE. TOTAL RNA-SEQUENCING WILL ALSO BE PERFORMED ON PBMCS TREATED WITH THE TOP 100 COMPOUNDS AND T CELL FATE CONFIRMED USING PUBLISHED AND ANNOTATED GENE SIGNATURES FOR EACH T CELL SUBSET. MODULATION OF IMMUNE PATHWAYS AND SIGNATURES WILL ALSO BE ASSESSED TO IDENTIFY POTENTIAL MECHANISMS OF ACTION FOR EACH COMPOUND. GRANULAR INVESTIGATION OF THE IMPACT OF THESE TOP 100 COMPOUNDS ON PLASMACYTOID DENDRITIC CELLS, CONVENTIONAL DENDRITIC CELLS AND CD4+ T CELLS WILL BE PERFORMED USING DIRECTED AND CUSTOMIZED FLOW CYTOMETRY PANELS. THESE EXPERIMENTS WILL ALLOW FOR CONFIRMATION OF IMMUNE POTENTIATORS OF T CELL FATE IN HUMAN CELL SYSTEMS AND FILTER DOWN THE TOP COMPOUNDS WITH CAPACITY TO MODULATE T CELL FATES. DR. TOMALKA WILL COORDINATE ACTIVITIES WITH DR. ESSER-KAHN AND THE OTHER INVESTIGATORS ON THIS CONTRACT TO ENSURE TIMELY COMPLETION OF PLANNED ASSAYS. DR. TOMALKA WILL BE RESPONSIBLE FOR GUIDING ANALYSIS OF THE DATA AND FOR PREPARING AND GIVING UPDATE PRESENTATIONS TO THE CONSORTIUM AS WELL AS PREPARING SEMI-ANNUAL AND ANNUAL REPORTS. DR. TOMALKA WILL PROVIDE HIS TECHNICAL AND THEORETICAL GUIDANCE, AS NEEDED, TO OTHER INVESTIGATORS TO ASSIST IN DESIGN, COMPLETION AND ANALYSIS OF THEIR ASSAYS. DR. TOMALKA WILL BE RESPONSIBLE FOR ASSISTING IN WRITING AND EDITING ANY MANUSCRIPTS WHICH COME FROM THE WORK”
No confirmed match on the Consolidated Screening List (screened Nov 10, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
